Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 16/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.55 |
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2361886 | 0.84 | SIGMAR1 (0.56) | SIGMAR1OPRK1CYP3A4CYP2D6TSHR | |
| SCHEMBL3529740 | 0.81 | SIGMAR1 (0.66) | SIGMAR1OPRK1CYP3A4CYP2D6TSHR | |
| SCHEMBL10867328 | 0.81 | SIGMAR1 (0.66) | SIGMAR1OPRK1CYP3A4CYP2D6TSHR | |
| Hydrochloric Acid SCHEMBL5630513 | 0.76 | SIGMAR1 (0.62) | SIGMAR1OPRK1CYP3A4CYP2D6TSHR | |
| Hydrochloric Acid SCHEMBL5630517 | 0.76 | SIGMAR1 (0.62) | SIGMAR1OPRK1CYP3A4CYP2D6TSHR | |
| Hydrochloric Acid SCHEMBL6350297 | 0.73 | SIGMAR1 (0.59) | SIGMAR1OPRK1CYP3A4CYP2D6TSHR | |
| Hydrochloric Acid SCHEMBL6478894 | 0.73 | SIGMAR1 (0.59) | SIGMAR1OPRK1CYP3A4CYP2D6TSHR | |
| SCHEMBL5935264 | 0.73 | SIGMAR1 (1.00) | SIGMAR1OPRK1CYP3A4CYP2D6TSHR | |
| SCHEMBL3174438 | 0.72 | OPRK1 (0.58) | SIGMAR1OPRK1CYP3A4CYP2D6TSHR | |
| SCHEMBL10801595 | 0.72 | SIGMAR1 (0.58) | SIGMAR1OPRK1CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6656930-B2 | Treatment of central nervous system (CNS) dysfunctions, neurodegenerative diseases and neurotoxic injury following hypoxia, anoxia or ischemia of stroke, cardiac arrest or perinatal asphyxia; antipsychotic and -convulsant agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-12-02 | — | — | US | disclosed |
| US-20020045624-A1 | Aralkyl diaxabicycloalkane derivatives for CNS disorders | BOWEN WAYNE D (US) | 2002-04-18 | — | — | US | disclosed |
| US-6310064-B1 | ADMINISTERING TO TREAT CEREBRAL ISCHEMIA OR A PSYCHOTIC DISORDER | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE OF DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-10-30 | — | — | US | disclosed |
| US-5656625-A | ANTIISCHEMIC AGENT, PSYCHOLOGICAL DISORDER, ANTICONVULSANT | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-12 | — | — | US | disclosed |
| US-5571832-A | Nitrogen-containing cyclohetero alkylamino aryl derivatives for CNS disorders | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-11-05 | — | — | US | disclosed |
| US-5346908-A | Anticonvulsant | NATIONAL INSTITUTES OF HEALTH (US) | 1994-09-13 | — | — | US | disclosed |
| WO-1994006794-A1 | ARALKYL DIAZABICYCLOALKANE DERIVATIVES FOR CNS DISORDERS | NATIONAL INSTITUTES OF HEALTH (US) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045624-A1 | Aralkyl diaxabicycloalkane derivatives for CNS disorders | HYPK, AHNAK, DGKZ | SIGMAR1 579/4885OPRK1 172/4885CYP3A4 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.